Eurofins buys drug ingredient contractor Alphora Research

By Gareth Macdonald contact

- Last updated on GMT

iStock/JK1991
iStock/JK1991

Related tags: Pharmacology, Active ingredient

Eurofins Scientific has acquired drug ingredient manufacturing and testing services firm Alphora Research, Inc.

The deal, financial terms of which were not disclosed, will see Mississauga, Canada-based Alphora two facilities join Eurofins’ network of drug testing laboratories.

Alphora focuses on the production and testing of active pharmaceutical ingredients (APIs), including those made using multi-step syntheses, cytotoxics and highly potent ingredients. The firm employs 100 people.

According to its website​, Alphora expects to generate revenue of C$30m ($22.6) in 2017.

Eurofins described the deal as its entry into what it calls the contract research, development and manufacturing organization (CRDMO) market.

CEO Gilles Martin said: “We are pleased to welcome Alphora to the Eurofins Group. Alphora’s competencies and footprint further strengthen Eurofins’ global leadership in the rapidly-growing biopharmaceutical testing market​.”

Eurofins declined to comment further.

Testing capacity

The addition of Alphora’s testing capabilities is in keeping with Eurofins’ expansion of its biopharmaceutical testing services capacity.

Last August​ Eurofins said it was adding 4,400m2 of lab space at its bioanalytical facility in Dungarvan, Ireland and committed to a further 1,800m2 at a second site nearby.

In March this year it said it will spend £4m ($5m) on a facility in Livingston, Scotland.

Related news

Show more

Follow us

Products

View more

Webinars